Ketorolac-dextran conjugates: Synthesis, in vitro and in vivo evaluation

Open access

Ketorolac-dextran conjugates: Synthesis, in vitro and in vivo evaluation

Ketorolac is a non-steroidal anti-inflammatory drug. Dextran conjugates of ketorolac (KD) were synthesized and characterized to improve ketorolac aqueous solubility and reduce gastrointestinal side effects. An N-acylimidazole derivative of ketorolac (KAI) was condensed with a model carrier polymer, dextran of different molecular masses (40000, 60000, 110000 and 200000). IR spectral data confirmed formation of ester bonding. Ketorolac contents were evaluated by UV-spectrophotometric analysis. The molecular mass was determined by measuring viscosity using the Mark-Howink-Sakurada equation. In vitro hydrolysis studies were performed in aqueous buffers (pH 1.2, 7.4, 9) and in 80% (V/V) human plasma (pH 7.4). At pH 9, a higher rate of ketorolac release from KD was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics. In vivo biological screening in mice and rats indicated that conjugates retained analgesic and anti-inflammatory activities with significantly reduced ulcerogenicity compared to the parent drug.

D. R. Brocks and F. Jamali, Pharmacokinetics of ketorolac tromethamine, Clin. Pharmacokin.23 (1992) 415-427.

W. Wagner, P. Khanna and D. E. Furst, Nonsteroidal Anti-inflammatory Drugs, Disease-modifying Antirheumatic Drugs, Nonopioid Analgesics and Drugs Used in Gout, in Basic and Clinical Pharmacology (Ed. B. G. Katzung), 9th ed., McGraw-Hill, New York 2004, pp. 586.

V. Cioli, S. Putzolu, V. Rossi, P. S. Barcellona and C. Corradino, The role of direct tissue contact in the production of gastro-intestinal ulcers by anti-inflammatory drugs in rats, Toxicol. Appl. Pharmacol.50 (1979) 283-289; DOI: 10.1016/0041-008X(79)90153-4.

K. D. Rainsford, Mechanisms of gastrointestinal toxicity of non-steoridal anti-inflammatory drugs, Scand. J. Gastroenterol. Suppl.163 (1989) 9-16.

C. Hawkey, L. Laine, T. Simon, A. Beaulieu, J. Maldonado-Cocco, E. Acevedo, A. Shahane, H. Quan, J. Bolognese and E. Mortensen, Comparison of the effect of rofecoxib, ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double blind, placebo-controlled trial, Arthritis Rheum.43 (2000) 370-377; DOI: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D.

G. Giammona, G. Puglisi, B. Carlisi, A. S. Pignatello and A. Caruso, Polymeric prodrug: α,β polymeric (N-hydroxyethyl)-DL-aspartamide as a macromolecular carrier for non-steroidal anti-inflammatory agents, Int. J. Pharm.57 (1989) 55-62; DOI: 10.1016/0378-5173(89)90263-9.

E. Roseeuw, V. Coessens, E. Schacht, B. Vrooman, D. Domurado and G. Marchall, Polymeric prodrugs of antibiotics with improved efficiency, J. Mater. Sci. Mater. Med.10 (1999) 743-746; DOI: 10.1023/A:1008991508877.

M. Zovko, B. Zorc, P. Novak, P. Tepeš, B. Cetina-Čizmek and M. Horvat, Macromolecular prodrugs XI. Synthesis and characterization of polymer-estradiol conjugate, Int. J. Pharm.285 (2004) 35-41; DOI: 10.1016/j.ijpharm.2004.07.013.

K. Hoste, K. De Winne and E. Schacht, Polymeric prodrugs, Int. J. Pharm.277 (2004) 119-131; DOI: 10.1016/j.ijpharm.2003.07.016.

A. D. Virnik, K. P. Khomvakov and I. F. Skokova, Dextran and its derivatives, Russ. Chem. Rev.44 (1975) 588-602; DOI: 10.1070/RC1975v044n07ABEH002363.

C. Larsen, Dextran prodrugs - structure and stability in relation to therapeutic activity, Adv. Drug Deliv. Rev.3 (1989) 103-116; DOI: 10.1016/0169-409X(89)90006-9.

C. Larsen and M. Johansen, Macromolecular prodrugs XI: Regeneration rates of various NSAID compounds from their corresponding dextran ester prodrugs in aqueous buffer and in different biological media, Acta. Pharm. Nord.2 (1989) 57-65.

C. Larsen and M. Johansen, Macromolecular prodrugs I. Kinetics and mechanism of hydrolysis of O-benzoyl dextran conjugates in aqueous buffer and human plasma, Int. J. Pharm.27 (1985) 205-218; DOI: 10.1016/0378-5173(85)90070-5.

S. Ahmad, R. F. Tester, A. Corbett and J. Karkalas, Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis, Carbohydr. Res.341 (2006) 2694-2701; DOI: 10.1016/j.carres.2006.08.015.

S. K. Shrivastava, D. K. Jain and P. Trivedi, Dextrans-potential polymeric drug carriers for flurbiprofen, Pharmazie58 (2003) 389-391.

A. J. Hao, Y. D. Deng, X. B. Suo and Y. H. Cao, Synthesis and characteristics of the fluorouracildextran conjugates, Pharmazie61 (2006) 489-490.

P. Bue, A. R. Holmberg, M. Márquez, J. E. Westlin, S. Nilsson and P. U. Malmstrom, Intravesical administration of EGF-dextran conjugates in patients with superficial bladder cancer, Eur. Urol.38 (2000) 584-589; DOI: 10.1159/000020335.

G. S. Mishra, Molecular Weight Determination, in Introductory Polymer Chemistry, 1st ed., Wiley Eastern Ltd., New Delhi 1993, pp. 99-117.

M. N. Ghosh, Some Common Evaluation Technics, in Fundamentals of Experimental Pharmacology, 2nd ed., Scientific Book Agency, Calcutta 1984, pp.144-151.

C. A. Winter, E. A. Risley and G. W. Nuss, Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs, Proc Soc. Exp. Biol. Med.111 (1962) 544-547.

V. R. Shanbhag, A. M. Crider, R. Gokhale, A. Harpalani and R. M. Dick, Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity, J. Pharm. Sci.81 (1992)149-154; DOI: 10.1002/jps.2600810210.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 173 173 9
PDF Downloads 65 65 6